Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
625 stopped studies mapped to Malignant Urinary System Neoplasm and descendants · 88% state a reason
Over the 625 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01649180 | NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant…(PrE0801) | Phase 2 | terminated | Jul 25, 2012 | PrECOG, LLC. | Closed due to prolonged enrollment timelines | Enrollment / accrual |
| NCT04579133 | Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for… | Phase 2 | terminated | Oct 8, 2020 | Latin American Cooperative Oncology Group | Not approved | Other (stated, no rule matched) |
| NCT01147536 | Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants… | Phase 2 | terminated | Jun 22, 2010 | Agenus Inc. | Sponsor's business decision | Sponsor / business decision |
| NCT02693717 | Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial… | Phase 2 | terminated | Feb 29, 2016 | M.D. Anderson Cancer Center | The trial was closed due to the changing efficacy of treatments for metastatic urothelial cancer. | Efficacy / futility |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in… | Phase 1 / Phase 2 | withdrawn | Jul 9, 2020 | NKGen Biotech, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT02581384 | Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma,… | Phase 1 / Phase 2 | terminated | Oct 21, 2015 | Dana-Farber Cancer Institute | The study closed primarily due to weak accrual, as well as study design limitations. | Enrollment / accrual |
| NCT01185366 | Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma | Phase 2 | terminated | Aug 19, 2010 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00853125 | Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney… | Phase 2 | terminated | Mar 2, 2009 | Rutgers, The State University of New Jersey | Slow accrual | Enrollment / accrual |
| NCT01438112 | Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer(BOND) | Phase 2 / Phase 3 | terminated | Sep 21, 2011 | CG Oncology, Inc. | Change in study design | Other (stated, no rule matched) |
| NCT01253668 | Brivanib Metastatic Renal Cell Carcinoma | Phase 2 | terminated | Dec 3, 2010 | Abramson Cancer Center at Penn Medicine | In November 2012, this study was permanently closed to new accrual at the request of the drug… | Drug supply |
| NCT03189186 | Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by… | Phase 1 | withdrawn | Jun 16, 2017 | University of California, Irvine | This study was closed due to extremely low accrual, as well as a change in care when using the… | Enrollment / accrual |
| NCT00324740 | Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer | Phase 1 / Phase 2 | terminated | May 11, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT03125200 | Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth… | Phase 1 | terminated | Apr 24, 2017 | ADC Therapeutics S.A. | Safety | Safety / toxicity |
| NCT02495103 | Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney… | Phase 1 / Phase 2 | terminated | Jul 13, 2015 | National Cancer Institute (NCI) | Vandetanib is no longer available as Sanofi has decided not to provide additional drug. All… | Other (stated, no rule matched) |
| NCT02853162 | Ablative tReatment of Inoperable REnal Cell Carcinoma Using STereotactic Body…(ARREST) | Phase 2 | terminated | Aug 2, 2016 | UMC Utrecht | Slow inclusion | Other (stated, no rule matched) |
| NCT04609800 | Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic…(CAROLINE) | — | withdrawn | Oct 30, 2020 | Ipsen | Unfavorable opinion of IRB/IEC | Other (stated, no rule matched) |
| NCT02947152 | HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma | Phase 1 | terminated | Oct 27, 2016 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT02131376 | Investigating a Novel Modifiable Factor Affecting Renal Function After Partial… | N/A | terminated | May 6, 2014 | Indiana University | slow accrual, interim analysis showed no statistical significance | Efficacy / futility |
| NCT02071719 | Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in… | — | terminated | Feb 26, 2014 | M. Labots | not stated | Not stated |
| NCT04262375 | A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer…(DOMINATION) | Phase 2 | withdrawn | Feb 10, 2020 | University Health Network, Toronto | Overall clinical activity (ORR) for oleclumab + durvalumab is minimal across tumor types and does… | Other (stated, no rule matched) |
| NCT01673386 | A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With…(TAURUS) | Phase 2 | terminated | Aug 28, 2012 | AVEO Pharmaceuticals, Inc. | Sponsor | Other (stated, no rule matched) |
| NCT02595918 | Nivolumab in Treating Patients With High-Risk Kidney Cancer Before Surgery | Phase 1 | terminated | Nov 4, 2015 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT01806064 | Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal… | Phase 1 / Phase 2 | terminated | Mar 7, 2013 | Tracon Pharmaceuticals Inc. | The study did not meet endpoint. | Other (stated, no rule matched) |
| NCT03540199 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced… | Phase 2 | withdrawn | May 30, 2018 | Fuda Cancer Hospital, Guangzhou | No participant enrolled | Enrollment / accrual |
| NCT02346955 | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in… | Phase 1 | terminated | Jan 27, 2015 | Famewave Ltd. | not stated | Not stated |
| NCT03498196 | A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer | Phase 1 / Phase 2 | terminated | Apr 13, 2018 | Baylor College of Medicine | The sponsor of this study has terminated the study due to poor enrollment. | Enrollment / accrual |
| NCT03719300 | Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC | Phase 2 | terminated | Oct 25, 2018 | Anchiano Therapeutics Israel Ltd. | Lack of efficacy | Efficacy / futility |
| NCT03598816 | PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for…(PIVOT-RCC) | Phase 2 | withdrawn | Jul 26, 2018 | Washington University School of Medicine | FDA Contingencies unresolved | Other (stated, no rule matched) |
| NCT04260360 | Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma | Phase 1 | withdrawn | Feb 7, 2020 | NanOlogy, LLC | Not initiated | Other (stated, no rule matched) |
| NCT03167151 | Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)(PemBla) | Phase 1 / Phase 2 | terminated | May 25, 2017 | University of Oxford | The study failed to recruit within the permitted timeframe | Enrollment / accrual |
| NCT02688348 | Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients… | N/A | withdrawn | Feb 23, 2016 | Jonsson Comprehensive Cancer Center | not stated | Not stated |
| NCT02212730 | A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell… | Phase 1 | terminated | Aug 8, 2014 | Merck Sharp & Dohme LLC | Terminated early due to low enrollment | Enrollment / accrual |
| NCT03407976 | Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies(APPEASE) | Phase 1 | terminated | Jan 23, 2018 | University of Utah | Funding source withdrew financial support prior to start of Phase II portion of study | Funding |
| NCT02169284 | Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery | Phase 2 | terminated | Jun 23, 2014 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02170389 | Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer | N/A | terminated | Jun 23, 2014 | Roswell Park Cancer Institute | sponsor having financial difficulties | Funding |
| NCT04073160 | TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab…(TRIO Bladder) | Phase 1 | withdrawn | Aug 29, 2019 | Daniel George, MD | Study will not be completed. No participants were enrolled. | Enrollment / accrual |
| NCT00953446 | Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of… | N/A | terminated | Aug 6, 2009 | Beth Israel Deaconess Medical Center | not stated | Not stated |
| NCT02089334 | Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal… | Phase 1 / Phase 2 | terminated | Mar 17, 2014 | Rexahn Pharmaceuticals, Inc. | not stated | Not stated |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid… | Phase 1 | terminated | Nov 17, 2017 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT02837991 | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell… | Phase 1 | terminated | Jul 20, 2016 | Celldex Therapeutics | Development of CDX-014 discontinued | Other (stated, no rule matched) |
| NCT03517995 | Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention | Phase 2 | withdrawn | May 8, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Grant not approved | Other (stated, no rule matched) |
| NCT00303719 | Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy | Phase 2 | terminated | Mar 17, 2006 | Masonic Cancer Center, University of Minnesota | IRB Study Closure | Other (stated, no rule matched) |
| NCT03927248 | PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer | Phase 1 / Phase 2 | withdrawn | Apr 25, 2019 | HealthPartners Institute | funding issues | Funding |
| NCT01355562 | Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney… | Phase 2 | withdrawn | May 18, 2011 | Loma Linda University | Primary Investigator is no longer employed at LLU as of 02/29/12. | Investigator |
| NCT00350688 | Bladder Cancer Chemoradiation Using Intensity Modulated Radiation Therapy | N/A | terminated | Jul 11, 2006 | Ottawa Hospital Research Institute | More advanced treatments superceded study design | Other (stated, no rule matched) |
| NCT03335059 | Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced…(RITE-USA) | Phase 3 | terminated | Nov 7, 2017 | Medical Enterprises Ltd. | poor enrollment | Enrollment / accrual |
| NCT03986398 | Nosocomial Infections During Total Prostatic Cystectomies (TPC) With Replacement…(Cranberry) | N/A | terminated | Jun 14, 2019 | Hopital Foch | In the perioperative setting of radical cystectomy-bladder replacement no improvement of UTI was… | Other (stated, no rule matched) |
| NCT04089163 | A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive… | Phase 1 | withdrawn | Sep 13, 2019 | Tocagen Inc. | Sponsor decision. | Sponsor / business decision |
| NCT00854022 | Genetic Susceptibility to Kidney Cancer | — | terminated | Mar 2, 2009 | Baylor College of Medicine | Funding ended | Funding |
| NCT02010203 | A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After… | Phase 1 / Phase 2 | terminated | Dec 12, 2013 | Heat Biologics | Inability to accrue due to changing treatment landscape (PD-1 approvals) | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 24 days agoSource updated Aug 12, 2021source: clinicaltrials